Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Dupilumab hits the mark for severe AD in younger children

Key clinical point: Dupilumab significantly improved symptoms of atopic dermatitis in grade school–aged children, according to new clinical trial results.

Major finding: In a cohort of children with severe AD, 33% achieved clear or nearly clear skin after 16 weeks of treatment with every 4-week dosing of the injectable medication, while 30% also achieved that mark when receiving a weight-based dose every 2 weeks, significantly better than those receiving placebo (P less than .0001 for both therapy arms) versus placebo).

Study details: Randomized, double-blind, placebo-controlled trial of 367 children aged 6-11 years of age with severe AD.

Disclosures: The study was funded by Regeneron and Sanofi. Dr. Paller reported receiving support from these two pharmaceutical companies, as well as from many others.

Citation:

FROM REVOLUTIONIZING AD 2020